Rx Price Increases Are Not Going Away, McKesson Assures Investors
This article was originally published in The Pink Sheet Daily
McKesson expects price increases to continue at rate seen in recent years, despite unexpected lack of price changes during this quarter, CEO says. Importance of price increases to wholesalers is "poorly understood" on Wall Street, McKesson acknowledges.
You may also be interested in...
Number of price increases in current quarter is lowest in four years, McKesson says. Wholesaler expects to meet full year earnings targets – assuming that “majority” of expected price increases are realized.
US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.
Whether CME for pain management has the intended impact on prescribing is likely focus of new ‘suite of studies’ intended to assess the opioid REMS program. The challenges for FDA include teasing out the impact of the risk management program amid all the other public health efforts on opioids.